North America Dry Eye Syndrome Market

North America Dry Eye Syndrome Market Size (2022 to 2027)

The North American market size for dry eye syndrome is projected to grow at a CAGR of 4.64% from 2022 to 2027 and be worth USD 2.75 billion by 2027 from USD 2.19 billion in 2022.

Factors such as an increase in the geriatric population, Y-O-Y rise in the prevalence of dry eye syndrome, change in lifestyle, poor dietary intake leading to vitamin A deficiency, and an increase in the prevalence of dry eye syndrome are expected to accelerate the overall growth of the dry eye syndrome market in North America during the forecast period. In addition, as the senior population grows, the incidence of dry eye syndrome will rise, boosting the market's healthy expansion. The most frequent dry eye is linked to a chronic ophthalmic condition, which affects an older population at a higher rate than adults.

Pharmaceutical companies' increasing R&D investments in new therapies could significantly impact the market. Furthermore, product introductions with high efficacies can improve the market's prospects due to increased awareness and incidence. In addition, the increased desire for better treatment outcomes and patient quality of life may propel the market forward. Sjogren's syndrome, lupus, scleroderma, rheumatoid arthritis, and diabetes are all on the rise, which is fueling market expansion. Other factors driving market expansion include increased spending on healthcare infrastructure development and an increase in the diagnosis rate among market players. Furthermore, increased use of mobile phones and laptops, frequent travel, rising pollution levels, increased awareness of the disease's diagnosis and treatment, and increased usage of contact lenses would boost the North American dry eye syndrome market in the forecast period. Soon, increased research and development will expand suitable opportunities for the growth of the dry eye syndrome market in this region.

Over the forecast period, the high cost of specialist dry eye medicines, combined with a complicated reimbursement landscape and the availability of alternative therapies, is projected to impede the dry eye syndrome market growth in the North American region. Lack of awareness, scarcity of qualified ophthalmologists, and the availability of alternative remedies is expected to stifle the market growth during the forecast period. Governments and institutions are expected to use new technologies to turn the obstacles posed by COVID-19 into possibilities. In addition, the dry eye syndrome market's growth is expected to be hampered in the coming years by the strict regulatory process for drug approval.

This research report on the North American dry eye syndrome market has been segmented and sub-segmented into the following categories.

By Drug Type:

• Anti-inflammatory Drugs
• Lubricant Eye Drops
• Autologous Serum Eye Drops
• Anti-Allergic
• Anti-Infectives
• Others

By Product:

• Liquid Drops
• Gel
• Liquid Wipes
• Eye Ointment
• Others 

By Distribution Channel:

• Hospital pharmacies
• Retail pharmacies
• Specialty clinics
• e-commerce
• Others

By Country:

• The United States
• Canada
• Rest of North America

Geographically, the North American region accounted for most of the global dry eye syndrome market share in 2021. Factors such as the region's aging population also contribute to the market's expansion. Several other factors, including increased computer or digital screen usage, may decrease blinking, contribute to DED symptoms, and push the entire market. The presence of significant producers in the U.S. and a high level of awareness and incidence of dry eye disease in the U.S. and Canada are expected to boost the growth of the dry eye syndrome market in North America. Furthermore, most of the population uses computers, with even more dealing with cell phones, digital devices, and tablet PCs daily. Smartphone-based ophthalmic consultation has become a lifeline for consultation. In addition, the introduction of new products to the market is fueling growth.

KEY MARKET PLAYERS:

Companies playing a significant role in the North America dry eye syndrome market profiled in this report are Alimera Science, Alcon Inc., Santen Pharmaceutical Co. Ltd., Allergan plc., Auven Therapeutics, Bausch + Lomb, GlaxoSmithKline plc, Bausch Health Companies Inc., Nicox S.A., Novartis AG, Otsuka Holdings Co. Ltd., AbbVie Inc. (Allergan PLC) and OASIS Medical.